CER-T Immunotherapy

About Anixa Biosciences

Anixa Biosciences is advancing a dual-platform approach to oncology, combining a next-generation CAR-T variant (CER-T) for cancer treatment with a novel vaccine platform targeting 'retired' tissue-specific proteins for cancer prevention. The company's most advanced programs are a breast cancer vaccine for triple-negative breast cancer (TNBC) and an ovarian cancer vaccine, both leveraging its proprietary vaccine technology. Led by a seasoned management team with deep experience in biotech and supported by a world-class scientific advisory board, Anixa is positioned to address significant unmet needs across multiple high-incidence cancers.

Therapeutic Areas